Do analysts rate ZIVO or INM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ZIVO or INM more profitable?

ZIVO Bioscience's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets ZIVO Bioscience N/A N/A -2,240.92% InMed Pharmaceuticals N/A -156.08% -123.90%

Do analysts rate ACTU or INM?

Actuate Therapeutics presently has a consensus target price of $10.50, indicating a potential upside of 2,151.77%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ACTU or INM more profitable?

InMed Pharmaceuticals' return on equity of -156.08% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -346.19% -178.40% InMed Pharmaceuticals N/A -156.08% -123.90%

Does the media favor ACTU or INM?

In the previous week, InMed Pharmaceuticals had 7 more articles in the media than Actuate Therapeutics. MarketBeat recorded 9 mentions for InMed Pharmaceuticals and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.61 beat InMed Pharmaceuticals' score of 0.57 indicating that Actuate Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Actuate Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INM or ?

Given 's higher possible upside, analysts plainly believe is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, INM or ?

has lower revenue, but higher earnings than InMed Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InMed Pharmaceuticals $4.94M 0.89 -$12.56M -$1.64 N/A N/A N/A N/A N/A N/A

Is INM or more profitable?

's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets InMed Pharmaceuticals N/A -156.08% -123.90% N/A N/A N/A

Does the media refer more to INM or ?

In the previous week, had 1145 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 1154 mentions for and 9 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.57 beat 's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 251 Very Positive mention(s) 287 Positive mention(s) 315 Neutral mention(s) 197 Negative mention(s) 104 Very Negative mention(s) Neutral

Do analysts recommend DARE or INM?

Dare Bioscience presently has a consensus price target of $6.50, suggesting a potential upside of 769.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Dare Bioscience is more favorable than InMed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 InMed Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor DARE or INM?

In the previous week, InMed Pharmaceuticals had 3 more articles in the media than Dare Bioscience. MarketBeat recorded 9 mentions for InMed Pharmaceuticals and 6 mentions for Dare Bioscience. InMed Pharmaceuticals' average media sentiment score of 0.57 beat Dare Bioscience's score of 0.30 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral InMed Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

InMed Pharmaceuticals (INM) Competitors

$1.34 +0.01 (+0.75%)

As of 03:24 PM Eastern

Compare

INM vs. ZIVO, ACTU, CYCN, DARE, and KPTI

Should you buy InMed Pharmaceuticals stock or one of its competitors? InMed Pharmaceuticals's main competitors and comparable companies include ZIVO Bioscience (ZIVO), Actuate Therapeutics (ACTU), Cyclerion Therapeutics (CYCN), Dare Bioscience (DARE), and Karyopharm Therapeutics (KPTI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

ZIVO Bioscience (NASDAQ:ZIVO) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, InMed Pharmaceuticals had 9 more articles in the media than ZIVO Bioscience. MarketBeat recorded 9 mentions for InMed Pharmaceuticals and 0 mentions for ZIVO Bioscience. InMed Pharmaceuticals' average media sentiment score of 0.57 beat ZIVO Bioscience's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
InMed Pharmaceuticals	Positive

ZIVO Bioscience has higher earnings, but lower revenue than InMed Pharmaceuticals. ZIVO Bioscience is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$15.85K	1,732.17	-$7.78M	-$1.40	N/A
InMed Pharmaceuticals	$4.94M	0.89	-$12.56M	-$1.64	N/A

ZIVO Bioscience's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	N/A	N/A	-2,240.92%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ZIVO Bioscience has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market.

12.8% of ZIVO Bioscience shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 21.5% of ZIVO Bioscience shares are held by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

InMed Pharmaceuticals beats ZIVO Bioscience on 8 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

Actuate Therapeutics has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

20.1% of InMed Pharmaceuticals shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

InMed Pharmaceuticals' return on equity of -156.08% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-346.19%	-178.40%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

InMed Pharmaceuticals has higher revenue and earnings than Actuate Therapeutics. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.87	N/A
InMed Pharmaceuticals	$4.94M	0.89	-$12.56M	-$1.64	N/A

In the previous week, InMed Pharmaceuticals had 7 more articles in the media than Actuate Therapeutics. MarketBeat recorded 9 mentions for InMed Pharmaceuticals and 2 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.61 beat InMed Pharmaceuticals' score of 0.57 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Actuate Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Actuate Therapeutics presently has a consensus target price of $10.50, indicating a potential upside of 2,151.77%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Actuate Therapeutics beats InMed Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to ?

InMed Pharmaceuticals (NASDAQ:INM) and (:) are related companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Given 's higher possible upside, analysts plainly believe is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

20.1% of InMed Pharmaceuticals shares are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

has lower revenue, but higher earnings than InMed Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94M	0.89	-$12.56M	-$1.64	N/A
	N/A	N/A	N/A	N/A	N/A

's return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	N/A	-156.08%	-123.90%
	N/A	N/A	N/A

In the previous week, had 1145 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 1154 mentions for and 9 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.57 beat 's score of 0.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
	251 Very Positive mention(s)	287 Positive mention(s)	315 Neutral mention(s)	197 Negative mention(s)	104 Very Negative mention(s)	Neutral

Summary

InMed Pharmaceuticals beats on 5 of the 9 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

InMed Pharmaceuticals has a net margin of 0.00% compared to Dare Bioscience's net margin of -803.80%. InMed Pharmaceuticals' return on equity of -156.08% beat Dare Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Dare Bioscience presently has a consensus price target of $6.50, suggesting a potential upside of 769.33%. Given Dare Bioscience's stronger consensus rating and higher probable upside, equities research analysts plainly believe Dare Bioscience is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Dare Bioscience has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 3.4% of Dare Bioscience shares are owned by insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, InMed Pharmaceuticals had 3 more articles in the media than Dare Bioscience. MarketBeat recorded 9 mentions for InMed Pharmaceuticals and 6 mentions for Dare Bioscience. InMed Pharmaceuticals' average media sentiment score of 0.57 beat Dare Bioscience's score of 0.30 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
InMed Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InMed Pharmaceuticals has higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	14.28	-$13.40M	-$0.70	N/A
InMed Pharmaceuticals	$4.94M	0.89	-$12.56M	-$1.64	N/A

Summary

Dare Bioscience beats InMed Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does InMed Pharmaceuticals compare to Karyopharm Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

In the previous week, InMed Pharmaceuticals had 8 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 9 mentions for InMed Pharmaceuticals and 1 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 1.82 beat InMed Pharmaceuticals' score of 0.57 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Very Positive
InMed Pharmaceuticals	Positive

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 0.9% of InMed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

InMed Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.07	-$196.04M	-$13.09	N/A
InMed Pharmaceuticals	$4.94M	0.89	-$12.56M	-$1.64	N/A

Karyopharm Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, InMed Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Karyopharm Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 2,590.69%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than InMed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
InMed Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InMed Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat InMed Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
InMed Pharmaceuticals	N/A	-156.08%	-123.90%

Summary

Karyopharm Therapeutics beats InMed Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get InMed Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INM vs. The Competition

Export

Metric	InMed Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.44M	$12.40B	$7.29B	$12.91B
Dividend Yield	N/A	2.63%	2.51%	22.89%
P/E Ratio	-0.82	807.80	275.68	25.25
Price / Sales	0.90	748.52	562.78	78.51
Price / Cash	N/A	86.65	77.16	53.04
Price / Book	4.19	9.19	10.54	5.92
Net Income	-$12.56M	$2.84B	$3.50B	$381.16M
7 Day Performance	0.75%	-4.30%	-4.13%	-4.32%
1 Month Performance	3.08%	-8.36%	-8.51%	-7.19%
1 Year Performance	-39.09%	-6.14%	2.12%	-4.99%

InMed Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INM InMed Pharmaceuticals	0.8421 of 5 stars	$1.34 +0.8%	N/A	-37.6%	$4.44M	$4.94M	N/A	6	Short Interest Increase
ZIVO ZIVO Bioscience	N/A	$4.10 +2.2%	N/A	-50.7%	$17.28M	$15.85K	N/A	10	Gap Down
ACTU Actuate Therapeutics	2.2095 of 5 stars	$0.69 -14.9%	$10.50 +1,419.5%	-94.2%	$16.59M	N/A	N/A	12	Gap Up High Trading Volume
CYCN Cyclerion Therapeutics	N/A	$3.49 +3.9%	N/A	N/A	$16.33M	$2.07M	N/A	30	Gap Up High Trading Volume
DARE Dare Bioscience	2.5672 of 5 stars	$0.80 -3.7%	$6.50 +710.5%	-64.7%	$15.78M	$1.03M	N/A	24	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INM) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InMed Pharmaceuticals (INM) Competitors

INM vs. ZIVO, ACTU, CYCN, DARE, and KPTI

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

Summary

How does InMed Pharmaceuticals compare to Actuate Therapeutics?

Summary

How does InMed Pharmaceuticals compare to ?

Summary

How does InMed Pharmaceuticals compare to Dare Bioscience?

Summary

How does InMed Pharmaceuticals compare to Karyopharm Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InMed Pharmaceuticals (INM) Competitors

INM vs. ZIVO, ACTU, CYCN, DARE, and KPTI

How does InMed Pharmaceuticals compare to ZIVO Bioscience?

Does the media favor ZIVO or INM?

Which has stronger earnings & valuation, ZIVO or INM?

Is ZIVO or INM more profitable?

Do analysts rate ZIVO or INM?

Which has more risk and volatility, ZIVO or INM?

Do institutionals and insiders believe in ZIVO or INM?

Summary

How does InMed Pharmaceuticals compare to Actuate Therapeutics?

Which has more volatility and risk, ACTU or INM?

Do institutionals & insiders believe in ACTU or INM?

Is ACTU or INM more profitable?

Which has better valuation & earnings, ACTU or INM?

Does the media favor ACTU or INM?

Do analysts rate ACTU or INM?

Summary

How does InMed Pharmaceuticals compare to ?

Do analysts prefer INM or ?

Do insiders & institutionals have more ownership in INM or ?

Which has better valuation & earnings, INM or ?

Is INM or more profitable?

Does the media refer more to INM or ?

Summary

How does InMed Pharmaceuticals compare to Dare Bioscience?

Is DARE or INM more profitable?

Do analysts recommend DARE or INM?

Which has more volatility and risk, DARE or INM?

Do institutionals & insiders hold more shares of DARE or INM?

Does the media favor DARE or INM?

Which has stronger earnings and valuation, DARE or INM?

Summary

How does InMed Pharmaceuticals compare to Karyopharm Therapeutics?

Does the media refer more to KPTI or INM?

Do insiders & institutionals hold more shares of KPTI or INM?

Which has better valuation and earnings, KPTI or INM?

Which has more risk & volatility, KPTI or INM?

Do analysts recommend KPTI or INM?

Is KPTI or INM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INM vs. The Competition

InMed Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools